Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159971 | 0.83 | CTSB (0.51) | SMN1; SMN2ALDH1A1KMT2AMEN1MAPK1 | |
| Hydrochloric Acid SCHEMBL7971724 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL922423 | 0.77 | HTT (0.55) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL4154654 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| Hydrochloric Acid SCHEMBL7562401 | 0.76 | HTT (0.53) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL3975661 | 0.75 | HRH3 (0.59) | SMN1; SMN2KMT2AHTTMEN1MAPK1 | |
| SCHEMBL334535 | 0.75 | L3MBTL1 (0.74) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL922812 | 0.75 | KMT2A (0.45) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL921506 | 0.74 | KMT2A (0.42) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL16400206 | 0.74 | KDM4E (0.74) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | SMN1; SMN2 2335/4885ALDH1A1 2743/4885KMT2A 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.